دورية أكاديمية
COVID-19-Associated Pulmonary Aspergillosis, Fungemia, and Pneumocystosis in the Intensive Care Unit: a Retrospective Multicenter Observational Cohort during the First French Pandemic Wave
| العنوان: | COVID-19-Associated Pulmonary Aspergillosis, Fungemia, and Pneumocystosis in the Intensive Care Unit: a Retrospective Multicenter Observational Cohort during the First French Pandemic Wave |
|---|---|
| المؤلفون: | Bretagne, Stéphane, Sitbon, Karine, Botterel, Françoise, Dellière, Sarah, Letscher-Bru, Valérie, Chouaki, Taieb, Bellanger, Anne-Pauline, Bonnal, Christine, Fekkar, Arnault, Persat, Florence, Costa, Damien, Bourgeois, Nathalie, Dalle, Frédéric, Lussac-Sorton, Florian, Paugam, André, Cassaing, Sophie, Hasseine, Lilia, Huguenin, Antoine, Guennouni, Nadia, Mazars, Edith, Le Gal, Solène, Sasso, Milène, Brun, Sophie, Cadot, Lucile, Cassagne, Carole, Cateau, Estelle, Gangneux, Jean-Pierre, Moniot, Maxime, Roux, Anne-Laure, Tournus, Céline, Desbois-Nogard, Nicole, Le Coustumier, Alain, Moquet, Olivier, Alanio, Alexandre, Dromer, Françoise |
| المساهمون: | Centre National de Référence Mycoses Invasives et Antifongiques - National Reference Center Invasive Mycoses & Antifungals (CNRMA), Institut Pasteur Paris (IP)-Université Paris Cité (UPCité), Génomique évolutive, modélisation et santé (GEMS), Institut Pasteur Paris (IP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Laboratoire de Parasitologie-Mycologie CHU Saint Louis, Paris, Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal Paris, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Mycologie moléculaire - Molecular Mycology, CHU Henri Mondor Créteil, Laboratoire de Parasitologie et de Mycologie Médicale Strasbourg, Les Hôpitaux Universitaires de Strasbourg (HUS), Laboratoire de parasitologie et de mycologie médicales CHU Amiens, CHU Amiens-Picardie, Service de parasitologie et mycologie CHRU de Besançon, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), AP-HP - Hôpital Bichat - Claude Bernard Paris, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Pitié-Salpêtrière AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre d'Immunologie et des Maladies Infectieuses (CIMI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Service de parasitologie et mycologie médicale Hôpital de la Croix Rousse, Lyon, Hôpital de la Croix-Rousse CHU - HCL, Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), CHU Rouen, Normandie Université (NU), Laboratoire de Parasitologie-Mycologie (CHU de Montpellier), Pôle Biologie-Pathologie CHRU Montpellier, Centre Hospitalier Régional Universitaire Montpellier (CHRU Montpellier)-Centre Hospitalier Régional Universitaire Montpellier (CHRU Montpellier), Laboratoire de parasitologie mycologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), CHU Bordeaux Bordeaux, Hôpital Cochin AP-HP, Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Laboratoire de Parasitologie-Mycologie, Nice, Université Nice Sophia Antipolis (1965 - 2019) (UNS)-Centre Hospitalier Universitaire de Nice (CHU Nice)-Université Côte d'Azur (UCA), Hôpital universitaire Robert Debré Reims, Epidémiosurveillance de protozooses à transmission alimentaire et vectorielle (ESCAPE), Université de Reims Champagne-Ardenne (URCA)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES), Imagine - Institut des maladies génétiques (IHU) (Imagine - U1163), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), CHU Necker - Enfants Malades AP-HP, Centre hospitalier Valenciennes, Nord, Laboratoire de Parasitologie et Mycologiede CHRU Brest, Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Hôpital Universitaire Carémeau Nîmes (CHU Nîmes), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Service de Parasitologie Avicenne, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Avicenne AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Sorbonne Paris Nord, CHU Montpellier, Centre Hospitalier Régional Universitaire Montpellier (CHRU Montpellier), Institut Hospitalier Universitaire Méditerranée Infection (IHU Marseille), Vecteurs - Infections tropicales et méditerranéennes (VITROME), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées Brétigny-sur-Orge (IRBA), Centre hospitalier universitaire de Poitiers (CHU Poitiers), Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique EHESP (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), CHU Clermont-Ferrand, Hôpital Raymond Poincaré AP-HP, Hôpital Ambroise Paré AP-HP, Centre Hospitalier de Saint-Denis Ile-de-France, Centre Hospitalier Universitaire de Martinique Fort-de-France, Martinique, Centre Hospitalier de Beauvais, Institut Pasteur Paris (IP)-Centre National de la Recherche Scientifique (CNRS), The NRCMA is supported by Santé Publique France and Institut Pasteur |
| المصدر: | ISSN: 2165-0497 ; Microbiology Spectrum ; https://hal.sorbonne-universite.fr/hal-03404538Test ; Microbiology Spectrum, 2021, 9 (2), pp.e0113821. ⟨10.1128/Spectrum.01138-21⟩. |
| بيانات النشر: | HAL CCSD American Society for Microbiology |
| سنة النشر: | 2021 |
| المجموعة: | Université de Toulon: HAL |
| مصطلحات موضوعية: | Aspergillus, COVID-19, France, aspergillosis, critical care, fungemia, pneumocystosis, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, [SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie |
| الوصف: | International audience ; The aim of this study was to evaluate diagnostic means, host factors, delay of occurrence, and outcome of patients with COVID-19 pneumonia and fungal coinfections in the intensive care unit (ICU). From 1 February to 31 May 2020, we anonymously recorded COVID-19-associated pulmonary aspergillosis (CAPA), fungemia (CA-fungemia), and pneumocystosis (CA-PCP) from 36 centers, including results on fungal biomarkers in respiratory specimens and serum. We collected data from 154 episodes of CAPA, 81 of CA-fungemia, 17 of CA-PCP, and 5 of other mold infections from 244 patients (male/female [M/F] ratio = 3.5; mean age, 64.7 ± 10.8 years). CA-PCP occurred first after ICU admission (median, 1 day; interquartile range [IQR], 0 to 3 days), followed by CAPA (9 days; IQR, 5 to 13 days), and then CA-fungemia (16 days; IQR, 12 to 23 days) (P < 10-4). For CAPA, the presence of several mycological criteria was associated with death (P < 10-4). Serum galactomannan was rarely positive (<20%). The mortality rates were 76.7% (23/30) in patients with host factors for invasive fungal disease, 45.2% (14/31) in those with a preexisting pulmonary condition, and 36.6% (34/93) in the remaining patients (P = 0.001). Antimold treatment did not alter prognosis (P = 0.370). Candida albicans was responsible for 59.3% of CA-fungemias, with a global mortality of 45.7%. For CA-PCP, 58.8% of the episodes occurred in patients with known host factors of PCP, and the mortality rate was 29.5%. CAPA may be in part hospital acquired and could benefit from antifungal prescription at the first positive biomarker result. CA-fungemia appeared linked to ICU stay without COVID-19 specificity, while CA-PCP may not really be a concern in the ICU. Improved diagnostic strategy for fungal markers in ICU patients with COVID-19 should support these hypotheses. IMPORTANCE To diagnose fungal coinfections in patients with COVID-19 in the intensive care unit, it is necessary to implement the correct treatment and to prevent them if ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/34668768; hal-03404538; https://hal.sorbonne-universite.fr/hal-03404538Test; https://hal.sorbonne-universite.fr/hal-03404538/documentTest; https://hal.sorbonne-universite.fr/hal-03404538/file/Spectrum.01138-21.pdfTest; PUBMED: 34668768 |
| DOI: | 10.1128/Spectrum.01138-21 |
| الإتاحة: | https://doi.org/10.1128/Spectrum.01138-21Test https://hal.sorbonne-universite.fr/hal-03404538Test https://hal.sorbonne-universite.fr/hal-03404538/documentTest https://hal.sorbonne-universite.fr/hal-03404538/file/Spectrum.01138-21.pdfTest |
| حقوق: | info:eu-repo/semantics/OpenAccess |
| رقم الانضمام: | edsbas.4C99D420 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1128/Spectrum.01138-21 |
|---|